ClinicalTrials.gg

Program

AP 1903 reagent

Also written as “Rimiducid (AP1903)”, “BPX-501 and Rimiducid” and “Rimiducid”.

Its studies are mostly in Thymoma · Primary Immunodeficiency Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Hematologic Neoplasms · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Sep 29, 20176 company-led studies, 3 open or runningNext primary completion: Jun 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bellicum Pharmaceuticals52 open or runningphase 2since Sep 29, 2017Mar 24, 2009none ahead
Beijing Biotech11 open or runningphase 2since May 14, 2026May 14, 2026Jun 14, 2027phase 2 · NCT07598955

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2009First study: phase 1 study in Castrate Resistant Prostate Cancer (CRPC)New to Bellicum PharmaceuticalsBellicum Pharmaceuticals · NCT00868595 · 18 enrolled · United States
  2. Mar 21, 2013Phase 1 study in Neoplasm MetastasisBellicum Pharmaceuticals · NCT01823978 · 19 enrolled · United States
  3. Aug 28, 2014Phase 1 study in Primary Immunodeficiency DiseasesBellicum Pharmaceuticals · NCT02231710 · 1 enrolled · United States
  4. Sep 29, 2017Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaBellicum Pharmaceuticals · NCT03301168 · 120 enrolled · United States
  5. Feb 23, 2018Phase 1 study in Hematologic NeoplasmsBellicum Pharmaceuticals · NCT03459170 · 15 enrolled · Italy
  6. May 14, 2026Beijing Biotech's first study: phase 2 study in ThymomaNew to Beijing BiotechBeijing Biotech · NCT07598955 · 36 planned · China

Ahead

  1. Jun 14, 2027Primary completion: phase 2 study in ThymomaBeijing Biotech · NCT07598955

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07598955Thymoma · China2RecruitingBeijing BiotechJun 14, 202736
NCT03459170Hematologic Neoplasms · Italy1Active, not recruitingBellicum PharmaceuticalsSep 202215
NCT03301168Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States2Active, not recruitingBellicum PharmaceuticalsMay 11, 2021120
NCT02231710Primary Immunodeficiency Diseases · United States1TerminatedBellicum PharmaceuticalsSep 20151
NCT01823978Neoplasm Metastasis · United States1CompletedBellicum PharmaceuticalsMay 201619
NCT00868595Castrate Resistant Prostate Cancer (CRPC) · United States1CompletedBellicum PharmaceuticalsJul 201118

How it is read

Names in the registry

  • “Rimiducid (AP1903)”, 1 entry
  • “BPX-501 and Rimiducid”, 1 entry
  • “Rimiducid”, 1 entry
  • “rimiducid”, 1 entry
  • “AP1903”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.